相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Advances on immune-related adverse events associated with immune checkpoint inhibitors
Yong Fan et al.
FRONTIERS OF MEDICINE (2021)
Targeting Phosphatidylserine Enhances the Anti-tumor Response to Tumor-Directed Radiation Therapy in a Preclinical Model of Melanoma
Sadna Budhu et al.
CELL REPORTS (2021)
Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody
James J. Harding et al.
CLINICAL CANCER RESEARCH (2021)
Towards the Development of Long Circulating Phosphatidylserine (PS)- and Phosphatidylglycerol (PG)-Enriched Anti-Inflammatory Liposomes: Is PEGylation Effective?
Miriam E. Klein et al.
PHARMACEUTICS (2021)
The Pattern of Time to Onset and Resolution of Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors in Cancer: A Pooled Analysis of 23 Clinical Trials and 8,436 Patients
Si-Di Tang et al.
CANCER RESEARCH AND TREATMENT (2021)
IFN-gamma upregulates membranous and soluble PD-L1 in mesothelioma cells: potential implications for the clinical response to PD-1/PD-L1 blockade
Maria Pia Pistillo et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2020)
Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy
Xu Lei et al.
CANCER LETTERS (2020)
TIMs, TAMs, and PS- antibody targeting: implications for cancer immunotherapy
Adam S. Dayoub et al.
CELL COMMUNICATION AND SIGNALING (2020)
Resistance to Checkpoint Inhibition in Cancer Immunotherapy
Luisa Barrueto et al.
TRANSLATIONAL ONCOLOGY (2020)
Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis
Xiaoxiang Zhou et al.
BMC MEDICINE (2020)
Biology of phosphatidylserine (PS): basic physiology and implications in immunology, infectious disease, and cancer
David C. Calianese et al.
CELL COMMUNICATION AND SIGNALING (2020)
Targeting MerTK Enhances Adaptive Immune Responses After Radiation Therapy
Garth W. Tormoen et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2020)
The tumor microenvironment of colorectal cancer metastases: opportunities in cancer immunotherapy
Yasmin Kamal et al.
IMMUNOTHERAPY (2020)
Therapeutic aspects of the Axl/Gas6 molecular system
Rossella Di Stasi et al.
DRUG DISCOVERY TODAY (2020)
Expression of PD-1 and PD-L1 on Tumor-Infiltrating Lymphocytes Predicts Prognosis in Patients with Small-Cell Lung Cancer
Chenglong Sun et al.
ONCOTARGETS AND THERAPY (2020)
Comprehensive Analysis of the Expression, Relationship to Immune Infiltration and Prognosis of TIM-1 in Cancer
Xiaoxiao Kong et al.
FRONTIERS IN ONCOLOGY (2020)
Targeting phosphatidylserine for Cancer therapy: prospects and challenges
Wenguang Chang et al.
THERANOSTICS (2020)
PD-L1 Overexpression on Tumor-Infiltrating Lymphocytes Related to Better Prognosis of Colorectal Cancer
Ji-Lin Wang et al.
CLINICAL LABORATORY (2020)
A novel human anti-AXL monoclonal antibody attenuates tumour cell migration
Yanting Duan et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2019)
Phosphatidylserine receptor-targeting therapies for the treatment of cancer
Miso Park et al.
ARCHIVES OF PHARMACAL RESEARCH (2019)
Clinicopathological implications of TIM3+ tumor-infiltrating lymphocytes and the miR-455-5p/Galectin-9 axis in skull base chordoma patients
Jinpeng Zhou et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Efficacy and Safety of Bavituximab in Combination with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase II Clinical Trial
Ali A. Mokdad et al.
TARGETED ONCOLOGY (2019)
Stabilin Receptors: Role as Phosphatidylserine Receptors
Seung-Yoon Park et al.
BIOMOLECULES (2019)
TAM receptors, Phosphatidylserine, inflammation, and Cancer
Tal Burstyn-Cohen et al.
CELL COMMUNICATION AND SIGNALING (2019)
Targeting phosphatidylethanolamine and phosphatidylserine for imaging apoptosis in cancer
Junling Li et al.
NUCLEAR MEDICINE AND BIOLOGY (2019)
Interleukin-6 and adhesion molecules VCAM-1 and ICAM-1 as biomarkers of post-acute myocardial infarction heart failure
D. O. C. Lino et al.
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH (2019)
Phosphatidylserine: A cancer cell targeting biomarker
Bhupender Sharma et al.
SEMINARS IN CANCER BIOLOGY (2018)
Blockade of Tim-3 binding to phosphatidylserine and CEACAM1 is a shared feature of anti-Tim-3 antibodies that have functional efficacy
Catherine A. Sabatos-Peyton et al.
ONCOIMMUNOLOGY (2018)
Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer
D. F. Gerber et al.
ANNALS OF ONCOLOGY (2018)
Phase Ib Study of Bavituximab With Carboplatin and Pemetrexed in Chemotherapy-Naive Advanced Nonsquamous None-Small-Cell Lung Cancer
Juneko E. Grilley-Olson et al.
CLINICAL LUNG CANCER (2018)
Effects of phosphatidylserine-containing supported lipid bilayers on the polarization of macrophages
Hongxuan Quan et al.
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A (2018)
Blockade of TIM3 relieves immunosuppression through reducing regulatory T cells in head and neck cancer
Jian-Feng Liu et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)
Targeting Gas6/TAM in cancer cells and tumor microenvironment
Guiling Wu et al.
MOLECULAR CANCER (2018)
Crystal structure of the FAS1 domain of the hyaluronic acid receptor stabilin-2
Aleksandra Twarda-Clapa et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2018)
Immune-related adverse events from combination immunotherapy in cancer patients: A comprehensive meta-analysis of randomized controlled trials
Bo Zhang et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2018)
TIM-3, a promising target for cancer immunotherapy
Yayi He et al.
ONCOTARGETS AND THERAPY (2018)
Differential Interaction of Platelet-Derived Extracellular Vesicles With Circulating Immune Cells: Roles of TAM Receptors, CD11b, and Phosphatidylserine
Birgit Fendl et al.
FRONTIERS IN IMMUNOLOGY (2018)
Antibody targeting of phosphatidylserine for detection and immunotherapy of cancer
Daniela Noa Zohar et al.
IMMUNOTARGETS AND THERAPY (2018)
Antibody targeting of phosphatidylserine for the detection and immunotherapy of cancer
Olivier Belzile et al.
IMMUNOTARGETS AND THERAPY (2018)
TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action
Wenwen Du et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Phosphatidylserine Sensing by TAM Receptors Regulates AKT-Dependent Chemoresistance and PD-L1 Expression
Canan Kasikara et al.
MOLECULAR CANCER RESEARCH (2017)
Increased PD-1+ and TIM-3+ TILs during Cetuximab Therapy Inversely Correlate with Response in Head and Neck Cancer Patients
Hyun-Bae Jie et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Landscape of Combination Immunotherapy and Targeted Therapy to Improve Cancer Management
Leandro M. Colli et al.
CANCER RESEARCH (2017)
Phosphatidylserine is a global immunosuppressive signal in efferocytosis, infectious disease, and cancer
R. B. Birge et al.
CELL DEATH AND DIFFERENTIATION (2016)
MicroRNA target Fc receptors to regulate Ab-dependent Ag uptake in primary macrophages and dendritic cells
Afsar Raza Naqvi et al.
INNATE IMMUNITY (2016)
IMMUNOTHERAPY PD-1 says goodbye, TIM-3 says hello
Diana Romero
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Targeting TYRO3 inhibits epithelial-mesenchymal transition and increases drug sensitivity in colon cancer
C-W Chien et al.
ONCOGENE (2016)
Stabilin-2 modulates the efficiency of myoblast fusion during myogenic differentiation and muscle regeneration
Seung-Yoon Park et al.
NATURE COMMUNICATIONS (2016)
Antibody-Mediated Phosphatidylserine Blockade Enhances the Antitumor Responses to CTLA-4 and PD-1 Antibodies in Melanoma
Bruce D. Freimark et al.
CANCER IMMUNOLOGY RESEARCH (2016)
TiM-3 Regulates Distinct Functions in Macrophages
Ranferi Ocana-Guzman et al.
FRONTIERS IN IMMUNOLOGY (2016)
Tumor-infiltrating Tim-3(+) T cells proliferate avidly except when PD-1 is co-expressed: Evidence for intracellular cross talk
Jing Li et al.
ONCOIMMUNOLOGY (2016)
Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers
Michael J. Gray et al.
BREAST CANCER RESEARCH (2016)
Phosphatidylserine liposomes mimic apoptotic cells to attenuate atherosclerosis by expanding polyreactive IgM producing B1a lymphocytes
Hamid Hosseini et al.
CARDIOVASCULAR RESEARCH (2015)
Detection of circulating immune complexes of human IgA and beta 2 glycoprotein I in patients with antiphospholipid syndrome symptomatology
Jose A. Martinez-Flores et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2015)
A phase I clinical trial of bavituximab and paclitaxel in patients with HER2 negative metastatic breast cancer
Pavani Chalasani et al.
CANCER MEDICINE (2015)
TIMgenes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity
Gordon J. Freeman et al.
IMMUNOLOGICAL REVIEWS (2015)
TAM receptors, Gas6, and protein S: roles in inflammation and hemostasis
Jonathan H. M. van der Meer et al.
BLOOD (2014)
CD8(+) T Cell-Independent Tumor Regression Induced by Fc-OX40L and Therapeutic Vaccination in a Mouse Model of Glioma
Katherine A. Murphy et al.
JOURNAL OF IMMUNOLOGY (2014)
IDO-Independent Suppression of T Cell Effector Function by IFN-γ-Licensed Human Mesenchymal Stromal Cells
Raghavan Chinnadurai et al.
JOURNAL OF IMMUNOLOGY (2014)
Galectin-3 contributes to cisplatin-induced myeloid derived suppressor cells (MDSCs) recruitment in Lewis lung cancer-bearing mice
Tian Wang et al.
MOLECULAR BIOLOGY REPORTS (2014)
Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer
Raghunadharao Digumarti et al.
LUNG CANCER (2014)
Tim-3: An Emerging Target in the Cancer Immunotherapy Landscape
Ana C. Anderson
CANCER IMMUNOLOGY RESEARCH (2014)
The TAM family: phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancer
Douglas K. Graham et al.
NATURE REVIEWS CANCER (2014)
Evaluation of Tyro3 Expression, Gas6-Mediated Akt Phosphorylation, and the Impact of Anti-Tyro3 Antibodies in Melanoma Cell Lines
Stephen J. Demarest et al.
BIOCHEMISTRY (2013)
MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis
Rebecca S. Cook et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation
C. Andrew Stewart et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Ca2+ activation of cytosolic calpain induces the transition from apoptosis to necrosis in neutrophils with externalized phosphatidylserine
R. J. Francis et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2013)
Phosphatidylserine receptor BAI1 and apoptotic cells as new promoters of myoblast fusion
Amelia E. Hochreiter-Hufford et al.
NATURE (2013)
Stabilin-1 expression in tumor associated macrophages
Clement David et al.
BRAIN RESEARCH (2012)
Extracellular Low pH Modulates Phosphatidylserine-dependent Phagocytosis in Macrophages by Increasing Stabilin-1 Expression
Seung-Yoon Park et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Anti-TIM3 Antibody Promotes T Cell IFN-γ-Mediated Antitumor Immunity and Suppresses Established Tumors
Shin Foong Ngiow et al.
CANCER RESEARCH (2011)
Phase I Safety and Pharmacokinetic Study of Bavituximab, a Chimeric Phosphatidylserine-Targeting Monoclonal Antibody, in Patients with Advanced Solid Tumors
David E. Gerber et al.
CLINICAL CANCER RESEARCH (2011)
The immune functions of phosphatidylserine in membranes of dying cells and microvesicles
Benjamin Frey et al.
SEMINARS IN IMMUNOPATHOLOGY (2011)
Adaptor protein GULP is involved in stabilin-1-mediated phagocytosis
Seung-Yoon Park et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2010)
Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation
Masafumi Nakayama et al.
BLOOD (2009)
Recognition of Live Phosphatidylserine-Labeled Tumor Cells by Dendritic Cells: A Novel Approach to Immunotherapy of Skin Cancer
Michael R. Shurin et al.
CANCER RESEARCH (2009)
VCAM-1 directed immunoliposomes selectively target tumor vasculature in vivo
Sara Gosk et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2008)
Epidermal growth factor-like domain repeat of stabilin-2 recognizes phosphatidylserine during cell corpse clearance
Seung-Yoon Park et al.
MOLECULAR AND CELLULAR BIOLOGY (2008)
Identification of putative targets of DNA (cytosine-5) methylation-mediated transcriptional silencing using a novel conditionally active form of DNA methyltransferase 3a
Michael S. Samuel et al.
GROWTH FACTORS (2007)
Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating fcγ receptors
Jeffrey B. Stavenhagen et al.
CANCER RESEARCH (2007)
Antigen recognition induces phosphatidylserine exposure on the cell surface of human CD8+ T cells
Karin Fischer et al.
BLOOD (2006)
Plasma protein β-2-glycoprotein 1 mediates interaction between the anti-tumor monoclonal antibody 3G4 and anionic phospholipids on endothelial cells
Troy A. Luster et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Expression and role of Fc- and complement-receptors on human dendritic cells
Z Bajtay et al.
IMMUNOLOGY LETTERS (2006)
Apoptotic cells quench reactive oxygen and nitrogen species and modulate TNF-α/TGF-β1 balance in activated macrophages:: involvement of phosphatidylserine-dependent and -independent pathways
BF Serinkan et al.
CELL DEATH AND DIFFERENTIATION (2005)
Antitumor effects of a monoclonal antibody that binds anionic phospholipids on the surface of tumor blood vessels in mice
S Ran et al.
CLINICAL CANCER RESEARCH (2005)
Distinct localization of lipid rafts and externalized phosphatidylserine at the surface of apoptotic cells
H Ishii et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
分享论文
